Skip to main content

Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer.

Publication ,  Journal Article
Antonarakis, ES; Armstrong, AJ
Published in: Prostate Cancer Prostatic Dis
September 2011

The management of men with metastatic castration-resistant prostate cancer (CRPC) has taken several leaps forward in the past year, with the demonstration of improved overall survival with three novel agents (sipuleucel-T, cabazitaxel with prednisone and abiraterone acetate with prednisone), and a significant delay in skeletal-related events observed with denosumab. The pipeline of systemic therapies in prostate cancer remains strong, as multiple agents with a diverse array of mechanisms of action are showing preliminary signs of clinical benefit, leading to more definitive phase III confirmatory trials. In this review, which represents part 1 of a two-part series on metastatic CRPC, we will summarize the mechanisms of resistance to hormonal and chemotherapies and discuss the evolving landscape of treatment options for men with CRPC, with a particular focus on currently approved and emerging treatment options following docetaxel administration, as well as prognostic factors in this post-docetaxel state. As docetaxel remains the standard initial systemic therapy for men with metastatic CRPC for both palliative and life-prolonging purposes, knowledge of these evolving standards will help to optimize delivery of care and long-term outcomes.

Duke Scholars

Published In

Prostate Cancer Prostatic Dis

DOI

EISSN

1476-5608

Publication Date

September 2011

Volume

14

Issue

3

Start / End Page

192 / 205

Location

England

Related Subject Headings

  • Urology & Nephrology
  • Tumor Microenvironment
  • Treatment Failure
  • Taxoids
  • Standard of Care
  • Receptors, Androgen
  • Randomized Controlled Trials as Topic
  • Prostatic Neoplasms
  • Orchiectomy
  • Male
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Antonarakis, E. S., & Armstrong, A. J. (2011). Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer. Prostate Cancer Prostatic Dis, 14(3), 192–205. https://doi.org/10.1038/pcan.2011.23
Antonarakis, E. S., and A. J. Armstrong. “Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer.Prostate Cancer Prostatic Dis 14, no. 3 (September 2011): 192–205. https://doi.org/10.1038/pcan.2011.23.
Antonarakis ES, Armstrong AJ. Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2011 Sep;14(3):192–205.
Antonarakis, E. S., and A. J. Armstrong. “Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer.Prostate Cancer Prostatic Dis, vol. 14, no. 3, Sept. 2011, pp. 192–205. Pubmed, doi:10.1038/pcan.2011.23.
Antonarakis ES, Armstrong AJ. Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2011 Sep;14(3):192–205.

Published In

Prostate Cancer Prostatic Dis

DOI

EISSN

1476-5608

Publication Date

September 2011

Volume

14

Issue

3

Start / End Page

192 / 205

Location

England

Related Subject Headings

  • Urology & Nephrology
  • Tumor Microenvironment
  • Treatment Failure
  • Taxoids
  • Standard of Care
  • Receptors, Androgen
  • Randomized Controlled Trials as Topic
  • Prostatic Neoplasms
  • Orchiectomy
  • Male